NCT06912295

Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of HL-1186 in Healthy Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 76 (estimated)
• Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This single-center, randomized, double-blind, placebo-controlled, two-part study is designed to assess the safety, tolerability and PK of oral HL-1186 Tablet in healthy participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	HL-1186	HL-1186 tablet for oral administration.
DRUG	HL-1186 placebo	HL-1186 placebo tablet for oral administration.

Timeline

• Start date: 2025-03-21
• Primary completion: 2025-08-30
• Completion: 2025-10-09
• First posted: 2025-04-04
• Last updated: 2025-08-24

Locations

1 site across 1 country: China